Cagrilintide: Dosage & Administration
Part of the Cagrilintide Complete Guide
Partner
Shop Peptides at BioLongevity LabsResearch Peptides
BioLongevity Labs15% Off
We may earn a commission if you purchase through this link, at no extra cost to you.
Dosage Protocols
| Protocol | Dose | Route | Frequency |
|---|---|---|---|
| Monotherapy (Phase 2) | 0.3–4.5 mg | SC injection | Weekly |
| CagriSema combination | 2.4 mg cagri + 2.4 mg sema | SC injection | Weekly |
Dose escalation over 8–12 weeks to minimize GI side effects. Cagrilintide is not yet commercially available — dosing is from published clinical trial protocols.
Administration
Cagrilintide is administered as a subcutaneous injection. In CagriSema trials, both peptides are delivered in a single injection pen. Clinical formulations are pre-filled — no reconstitution required.
Timing
Weekly injection on the same day each week, at any time of day, with or without meals. Long-term use is anticipated (similar to GLP-1 agonist paradigm), though long-term data is still accumulating.
Storage
- Clinical trial formulations: refrigerate at 2–8°C
- Do not freeze
- Protect from light